Peginterferon ß-1a every 2 weeks increased achievement of no evidence of disease activity over 4 years in the ADVANCE and ATTAIN studies in patients with relapsing-remitting multiple sclerosis.

Arnold, Douglas L; Shang, Shulian; Dong, Qunming; Meergans, Matthias; Naylor, Maria L

Arnold, Douglas L; Shang, Shulian; Dong, Qunming; Meergans, Matthias; Naylor, Maria L.

Afiliação

Arnold DL; Montreal Neurological Institute, McGill University, and NeuroRx Research, Montreal, QC, Canada.
Shang S; Biogen, Cambridge, MA, USA.
Dong Q; Biogen, Cambridge, MA, USA.
Meergans M; Biogen, Zug, Switzerland.
Naylor ML; Biogen, 225 Binney St., Cambridge, MA 02142, USA.

Ther Adv Neurol Disord ; 11: 1756286418795085, 2018.

Article em En | MEDLINE | ID: mdl-30181780

Palavras-chave

multiple sclerosis; peginterferon ß-1a; pegylated interferon; relapse; relapsingremitting multiple sclerosis

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Prognostic_studies Idioma: En Ano de publicação: 2018 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google